Cullinan Oncology, Inc. stock is up 39.84% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 15 February’s closed higher than January. 100% of analysts rate it a buy.
Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!